MATT ABERNETHY - 12 Feb 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Financial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
12 Feb 2026
Net transactions value
-$1,131,297
Form type
4
Filing time
17 Feb 2026, 17:49:23 UTC
Previous filing
03 Feb 2026
Next filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ABERNETHY MATT Chief Financial Officer 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 17 Feb 2026 0001724097

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +2,133 +5.7% $0.000000 39,230 12 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $141,688 -1,151 -2.9% $123.10 38,079 12 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +2,241 +5.9% $0.000000 40,320 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $150,185 -1,210 -3% $124.12 39,110 13 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +2,566 +6.6% $0.000000 41,676 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $171,906 -1,385 -3.3% $124.12 40,291 13 Feb 2026 Direct F1
transaction NBIX Common Stock Award $0 +9,968 +25% $0.000000 50,259 13 Feb 2026 Direct F2
transaction NBIX Common Stock Tax liability $667,517 -5,378 -11% $124.12 44,881 13 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,133 -25% $0.000000 6,401 12 Feb 2026 Common Stock 2,133 Direct F3, F4
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,241 -33% $0.000000 4,484 13 Feb 2026 Common Stock 2,241 Direct F3, F5
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,566 -50% $0.000000 2,566 13 Feb 2026 Common Stock 2,566 Direct F3, F6
transaction NBIX Stock Option Award $0 +44,095 $0.000000 44,095 13 Feb 2026 Common Stock 44,095 $124.12 Direct F7
transaction NBIX Restricted Stock Unit Award $0 +7,735 $0.000000 7,735 13 Feb 2026 Common Stock 7,735 Direct F3, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
F2 On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
F3 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F4 This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,133 shares on February 12, 2026, and will vest as to 2,133 shares on February 12, 2027, 2,134 shares on February 12, 2028, and 2,134 shares on February 12, 2029, subject to the terms and conditions of the award.
F5 This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award.
F6 This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award.
F7 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F8 The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.